Bacterial microbiome of lungs in COPD

International Journal of COPD

Volumn 9, Issue , 2014, Pages 229-238

  Sze, Marc A ^a   Hogg, James C ^b   Sin, Don D ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Bacterial microbiome; Chronic obstructive pulmonary disease; Lungs

Indexed keywords

BACTERIAL FLORA; BRONCHIAL BRUSHING; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; HUMAN; INTESTINE FLORA; LUNG MICROBIOTA; LUNG PARENCHYMA; MEDICAL PROCEDURES; MEDICAL RESEARCH; MICROBIAL COMMUNITY; MICROBIAL DIVERSITY; MICROBIOME; MOUTH FLORA; NONHUMAN; PATHOGENESIS; RESPIRATORY TRACT INFECTION; REVIEW;

BACTERIAL MICROBIOME; CHRONIC OBSTRUCTIVE PULMONARY DISEASE; LUNGS;

ANTI-BACTERIAL AGENTS; DISEASE PROGRESSION; GASTROINTESTINAL TRACT; HUMANS; LUNG; MICROBIOTA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SMOKING;

EID: 84896889298     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S38932     Document Type: Review

References (94)

1. Torsvik V, Ovreas L. Microbial diversity and function in soil: from genes to ecosystems. Curr Opin Microbiol. 2002;5(3):240-245.
2. Relman DA. New technologies, human-microbe interactions, and the search for previously unrecognized pathogens. J Infect Dis. 2002; 186 Suppl 2:S254-S258.
3. Shanahan F. The host-microbe interface within the gut. Best Pract Res Clin Gastroenterol. 2002;16(6):915-931.
4. Rodriguez-Brito B, Li L, Wegley L, et al. Viral and microbial community dynamics in four aquatic environments. ISME J. 2010;4(6):739-751.
5. Dollive S, Chen YY, Grunberg S, et al. Fungi of the murine gut:episodic variation and proliferation during antibiotic treatment. PLoS One. 2013;8(8):e71806.
6. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R,Gordon JI. The human microbiome project. Nature. 2007;449(7164): 804-810.
7. Li K, Bihan M, Yooseph S, Methé BA. Analyses of the microbial diver-sity across the human microbiome. PLoS One. 2012;7(6):e32118.
8. Hoffmann C, Dollive S, Grunberg S, et al. Archaea and fungi of the human gut microbiome: correlations with diet and bacterial residents. PLoS One. 2013;8(6):e66019.
9. Scupham AJ, Presley LL, Wei B, et al. Abundant and diversefungal microbiota in the murine intestine. Appl Environ Microbiol. 2006;72(1):793-801.
10. Reyes A, Haynes M, Hanson N, et al. Viruses in the faecal microbiota of monozygotic twins and their mothers. Nature. 2010;466(7304): 334-338.
11. de Dombal FT, Burch PR, Watkinson G. Aetiology of ulcerative colitis. Gut. 1969;10(4):270-277.
12. Macfarlane GT, Macfarlane S. Human colonic microbiota: ecology, physiology and metabolic potential of intestinal bacteria. Scand J Gastroenterol Suppl. 1997;222:3-9.
13. Nesbitt B. On the presence of cholin and neurin in the intestinal canal during its complete obstruction: a research on autointoxication. J Exp Med. 1899;4(1):1-18.
14. Khoury KA, Floch MH, Herskovic T. Effects of neomycin and penicillin administration on mucosal proliferation of the mouse small intestine. With morphological and functional correlations. J Exp Med. 1969;129(5):1063-1078.
15. Ichinohe T, Pang IK, Kumamoto Y, et al. Microbiota regulates immune defense against respiratory tract influenza A virus infection. Proc Natl Acad Sci U S A. 2011;108(13):5354-5359.
16. Ferreira RB, Gill N, Willing BP, et al. The intestinal microbiota plays a role in Salmonella-induced colitis independent of pathogen colonization. PLoS One. 2011;6(5):e20338.
17. Erb-Downward JR, Thompson DL, Han MK, et al. Analysis of the lung microbiome in the "healthy" smoker and in COPD. PLoS One. 2011;6(2):e16384.
18. Pragman AA, Kim HB, Reilly CS, Wendt C, Isaacson RE. The lung microbiome in moderate and severe chronic obstructive pulmonary disease. PLoS One. 2012;7(10):1-10.
19. Morris A, Beck JM, Schloss PD, et al. Comparison of the respiratory microbiome in healthy non-smokers and smokers. Am J Respir Crit Care Med. 2013;187(10):1067-1075.
20. Bartlett JG, Chang TW, Gurwith M, Gorbach SL, Onderdonk AB. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med. 1978;298(10):531-534.
21. Knights D, Lassen KG, Xavier RJ. Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome. Gut. 2013;62(10):1505-1510.
22. Le Chatelier E, Nielsen T, Qin J, et al. Richness of human gut micro-biome correlates with metabolic markers. Nature. 2013;500(7464): 541-546.
23. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442.
24. World Health Organization. The global burden of disease: 2004 update.Geneva, Switzerland: World Health Organization Press; 2008. Available from: http://www.who.int/healthinfo/global_burden_disease/2004_ report_update/en/. Accessed December 28, 2013.
25. Fletcher C, Peto P. The natural history of chronic airflow obstruction. BMJ. 1977;1(6077):1645-1648.
26. Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med. 2010;182(5):598-604.
27. Franklin W, Lowell FC, Michelson AL, Schiller IW. Chronic obstructive pulmonary emphysema; a disease of smokers. Ann Intern Med. 1956;45(2):268-274.
28. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(26):2645-2653.
29. Di Stefano A, Turato G, Maestrelli P, et al. Airflow limitation in chronic bronchitis is associated with T-lymphocyte and macrophage infiltration of the bronchial mucosa. Am J Respir Crit Care Med. 1996;153(2): 629-632.
30. Saetta M, Di Stefano A, Maestrelli P, et al. Activated T-lymphocytes and macrophages in bronchial mucosa of subjects with chronic bronchitis. Am Rev Respir Dis. 1993;147(2):301-306.
31. Low TB, Greene CM, O'Neill SJ, McElvaney NG. Quantification and evaluation of the role of antielastin autoantibodies in the emphysematous lung. Pulm Med. 2011;2011:826160.
32. Sethi S, Evans N, Grant BJ, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 2002;347(7):465-471.
33. Anthonisen NR. The British hypothesis revisited. Eur Respir J. 2004;23(5):657-658.
34. Fletcher CM. Chronic bronchitis - its prevalence, nature, and pathogenesis. Am Rev Respir Dis. 1959;80(4):483-494.
35. Fletcher C, Peto R, Tinker C, Speizer F. The Natural History of Chronic Bronchitis and Emphysema. New York, NY, USA: Oxford University Press; 1976.
36. Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med. 1996;153(5):1530-1535.
37. Kanner RE, Anthonisen NR, Connett JE; Lung Health Study Research Group. Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the Lung Health Study. Am J Respir Crit Care Med. 2001;164(3):358-364.
38. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12): 1128-1138.
39. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10): 847-852.
40. Hilty M, Burke C, Pedro H, et al. Disordered microbial communities in asthmatic airways. PLoS One. 2010;5(1):e8578.
41. Huang YJ, Kim E, Cox MJ, et al. A persistent and diverse airway microbiota present during chronic obstructive pulmonary disease exacerbations. OMICS. 2010;14(1):9-59.
42. Sze MA, Dimitriu PA, Hayashi S, et al. The lung tissue microbiome in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;185(10):1073-1080.
43. Rabe KF, Hurd S, Anzueto A, et al; Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176(6): 532-555
44. Segal LN, Alekseyenko AV, Clemente JC, et al. Enrichment of lung microbiome with supraglottic taxa is associated with increased pulmonary inflammation. Microbiome. 2013;1:1-12.
45. Gleeson K, Eggli DF, Maxwell SL. Quantitative aspiration during sleep in normal subjects. Chest. 1997;111(5):1266-1272.
46. Satir P, Sleigh MA. The physiology of cilia and mucociliary interactions. Annu Rev Physiol. 1990;52:137-155.
47. Sibille Y, Reynolds HY. Macrophages and polymorphonuclear neu-trophils in lung defense and injury. Am Rev Respir Dis. 1990;141(2):471-501.
48. Smith CM, Kulkarni H, Radhakrishnan P, et al. Ciliary dyskinesia is an early feature of respiratory syncytial virus infection. Eur Respir J. March 21, 2013. [Epub ahead of print.]
49. Sagel SD, Davis SD, Campisi P, Dell SD. Update of respiratory tract disease in children with primary ciliary dyskinesia. Proc Am Thorac Soc. 2011;8(5):438-443.
50. Tambascio J, Lisboa RM, Passarelli Rde C, Martinez JA, Gastaldi AC.Adhesiveness and purulence of respiratory secretions: implications for mucociliary transport in patients with bronchiectasis. J Bras Pneumol. 2010;36(5):545-553.
51. Hogg JC, van Eeden S. Pulmonary and systemic response to atmosphericpollution. Respirology. 2009;14(3):336-346.
52. Rogers GB, Carroll MP, Serisier DJ, et al. Bacterial activity in cystic fibrosis lung infections. Respir Res. 2005;6:49.
53. Rogers GB, van der Gast CJ, Cuthbertson L, et al. Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition. Thorax. 2013;68(8):731-737.
54. Goddard AF, Staudinger BJ, Dowd SE, et al. Direct sampling of cystic fibrosis lungs indicates that DNA-based analyses of upper-airway specimens can misrepresent lung microbiota. Proc Natl Acad Sci U S A. 2012;109(34):13769-13774.
55. Charlson ES, Bittinger K, Haas AR, et al. Topographical continuity of bacterial populations in the healthy human respiratory tract. Am J Respir Crit Care Med. 2011;184(8):957-963.
56. Ramakrishnan VR, Ferril GR, Suh JD, Woodson T, Green TJ, King-dom TT. Upper and lower airways associations in patients with chronic rhinosinusitis and bronchiectasis. Int Forum Allergy Rhinol. 2013;3(11):921-927.
57. Berkhout MC, Rijntjes E, El Bouazzaoui LH, Fokkens WJ, Brimicombe RW, Heijerman HG. Importance of bacteriology in upper airways of patients with cystic fibrosis. J Cyst Fibros. 2013;12(5): 525-529.
58. Charlson ES, Chen J, Custers-Allen R, et al. Disordered microbial communities in the upper respiratory tract of cigarette smokers. PLoS One. 2010;5(12):e15216.
59. Lourenço RV, Klimek MF, Borowski CJ. Deposition and clearance of 2 micron particles in the tracheobronchial tree of normal subjects - smokers and nonsmokers. J Clin Invest. 1971;50(7):1411-1420.
60. Smaldone GC, Foster WM, O'Riordan TG, Messina MS, Perry RJ, Langenback EG. Regional impairment of mucociliary clearance in chronic obstructive pulmonary disease. Chest. 1993;103(5):1390-1396.
61. Fanta CH. Clinical aspects of mucus and mucous plugging in asthma. J Asthma. 1985;22(6):295-301.
62. Leopold PL, O'Mahony MJ, Lian XJ, Tilley AE, Harvey BG, Crystal RG. Smoking is associated with shortened airway cilia. PLoS One. 2009;4(12):e8157.
63. Sethi S. Bacterial infection and the pathogenesis of COPD. Chest. 2000;117(5 Suppl 1):286S-291S.
64. Quon BS, Gan WQ, Sin DD. Contemporary management of acute exacerbations of COPD: a systematic review and metaanalysis. Chest. 2008;133(3):756-766.
65. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689-698.
66. Reid DW, Latham R, Lamont IL, Camara M, Roddam LF. Molecular analysis of changes in Pseudomonas aeruginosa load during treatment of a pulmonary exacerbation in cystic fibrosis. J Cyst Fibros. 2013;12(6): 688-699.
67. Fodor AA, Klem ER, Gilpin DF, et al. The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations. PLoS One. 2012;7(9):e45001.
68. Sibley CD, Parkins MD, Rabin HR, Surette MG. The relevance of the polymicrobial nature of airway infection in the acute and chronic management of patients with cystic fibrosis. Curr Opin Investig Drugs. 2009;10(8):787-794.
69. Tunney MM, Einarsson GG, Wei L, et al. Lung microbiota and bacte-rial abundance in patients with bronchiectasis when clinically stable and during exacerbation. Am J Respir Crit Care Med. 2013;187(10): 1118-1126.
70. Larsen JM, Steen-Jensen DB, Laursen JM, et al. Divergent pro-inflammatory profile of human dendritic cells in response to commensal and pathogenic bacteria associated with the airway microbiota. PLoS One. 2012;7(2):e31976.
71. Forsythe P, Inman MD, Bienenstock J. Oral treatment with live Lactobacillus reuteri inhibits the allergic airway response in mice. Am J Respir Crit Care Med. 2007;175(6):561-569.
72. Karimi K, Inman MD, Bienenstock J, Forsythe P. Lactobacillus reuteri-induced regulatory T cells protect against an allergic airway response in mice. Am J Respir Crit Care Med. 2009;179(3):186-193.
73. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444(7122):1027-1031.
74. Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese and lean twins. Nature. 2009;457(7228):480-484.
75. Cho I, Yamanishi S, Cox L, et al. Antibiotics in early life alter the murine colonic microbiome and adiposity. Nature. 2012;488(7413):621-626.
76. Rohlke F, Stollman N. Fecal microbiota transplantation in relapsing Clostridium difficile infection. Therap Adv Gastroenterol. 2012;5(6): 403-420.
77. Smith MI, Yatsunenko T, Manary MJ, et al. Gut microbiomes of Malawian twin pairs discordant for kwashiorkor. Science. 2013; 339(6119):548-554.
78. Trehan I, Goldbach HS, LaGrone LN, et al. Antibiotics as part of the management of severe acute malnutrition. N Engl J Med. 2013;368(5): 425-435.
79. Graessler J, Qin Y, Zhong H, et al. Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflamma- tory and metabolic parameters. Pharmacogenomics J. 2013;13(6): 514-522.
80. Qin J, Li Y, Cai Z, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490(7418):55-60.
81. Markle JG, Frank DN, Mortin-Toth S, et al. Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity. Science. 2013;339(6123):1084-1088.
82. Karlsson FH, Fåk F, Nookaew I, et al. Symptomatic atherosclerosis is associated with an altered gut metagenome. Nat Commun. 2012;3:1245.
83. Koren O, Spor A, Felin J, et al. Human oral, gut, and plaque micro-biota in patients with atherosclerosis. Proc Natl Acad Sci U S A. 2011; 108 Suppl 1:4592-4598.
84. Flores R, Shi J, Fuhrman B, et al. Fecal microbial determinants of fecal and systemic estrogens and estrogen metabolites: a cross-sectional study. J Transl Med. 2012;10:253.
85. El Aidy S, Kunze W, Bienenstock J, Kleerebezem M. The microbiota and the gut-brain axis: insights from the temporal and spatial mucosal alterations during colonisation of the germfree mouse intestine. Benef Microbes. 2012;3(4):251-259.
86. Ohland CL, Kish L, Bell H, et al. Effects of Lactobacillus helveticus on murine behavior are dependent on diet and genotype and correlate with alterations in the gut microbiome. Psychoneuroendocrinology. 2013;38(9):1738-1747.
87. Russell SL, Gold MJ, Hartmann M, et al. Early life antibiotic-driven changes in microbiota enhance susceptibility to allergic asthma. EMBO Rep. 2012;13(5):440-447.
88. Dominguez-Bello MG, Costello EK, Contreras M, et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci U S A. 2010;107(26):11971-11975.
89. Renz-Polster H, David MR, Buist AS, et al. Caesarean section delivery and the risk of allergic disorders in childhood. Clin Exp Allergy. 2005;35(11):1466-1472.
90. Ekbom A, Brandt L, Granath F, Löfdahl CG, Egesten A. Increased risk of both ulcerative colitis and Crohn's disease in a population suffering from COPD. Lung. 2008;186(3):167-172.
91. Jess T, Loftus EV Jr, Harmsen WS, et al. Survival and cause specific mortality in patients with inflammatory bowel disease: a long term outcome study in Olmsted County, Minnesota, 1940-2004. Gut. 2006;55(9):1248-1254.
92. Biedermann L, Zeitz J, Mwinyi J, et al. Smoking cessation induces profound changes in the composition of the intestinal microbiota in humans. PLoS One. 2013;8(3):e59260.
93. Nos P, Domènech E. Management of Crohn's disease in smokers: is an alternative approach necessary? World J Gastroenterol. 2011;17(31): 3567-3574.
94. Mahid SS, Minor KS, Soto RE, Hornung CA, Galandiuk S. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc. 2006;81(11):1462-1471.